Eisai news from FierceBiotech
NewsEisai wins expert panel's approval for new sedative
Backed by a positive review from FDA staffers, an expert panel at the agency has recommended the agency approve Eisai's fospropofol disodium, a sedative designed for use in a number of procedures, Read more...
FDA staffers say that Eisai sedative appears safe
FDA staffers say that an experimental sedative developed by Eisai appears to be safe, but wants outside experts to consider whether it's safe enough to be administered by workers untrained in Read more...
Eisai drug flunks Parkinson's trial
Eisai's has halted development of Perampanel (E2007) for Parkinson's after the drug failed a late-stage trial. Compared with placebo, E2007 didn't show a significant difference in the primary Read more...
ALSO NOTED: Pharmaxis reports Phase II CF data; New Zealand publishes biotech industry stats; and much more...
> Pharmaxis announced today that a Phase II clinical trial in children with cystic fibrosis demonstrated excellent lung function improvement following three months treatment with Bronchitol that Read more...
Morphotek licenses anti-cancer antibody
Morphotek has inked a deal with Human Monoclonals International to get rights to a human monoclonal IgM antibody that is specific to a cancer cell surface antigen. The company hopes to develop a lead Read more...
TorreyPines plans layoffs in streamlining
TorreyPines Therapeutics is taking a lashing from some of the analysts for its decision to cut staff as it restructures the company and focuses on its lead development programs. Those programs Read more...
Eisai faces delay for cancer drug
The FDA has delayed Eisai's NDA submission for E7389 (eribulin mesylate) for third-line treatment of advanced breast cancer. The company was hoping to gain accelerated approval for the drug, but Read more...
ALSO NOTED: Agennix OK'd to launch late-stage lung cancer trial; QLT reorganizes; Ventana still resisting Roche bid; and much m
> Houston-based Agennix has been given a green light to launch a late-stage trial of a new therapy for lung cancer that includes an ingredient found in mother's milk. Talactoferrin closely Read more...
Eisai expands U.S. ops with $3.9B MGI buyout
A little over a week after announcing that it would explore its "strategic alternatives," MGI Pharma Read more...
ALSO NOTED: CMC to boost production at Bothell facility; Eisai buys antibody; Vectura pockets milestone, equity pay; and much m
> The Copenhagen-based CMC Biopharmaceuticals says it plans to increase production of therapeutic proteins after buying the former Icos's plant in Bothell. Icos was acquired at the beginning of Read more...
| Press ReleasesStatus of the E2007 Development Program Status of the E2007 Development Program - Termination of Parkinson's Disease Clinical Development and Focus on Neuropathic Pain and Epilepsy Indications Friday April 11 TOKYO, Japan, April 11 -- Read more... PRESS RELEASE: EISAI TO ACQUIRE MGI PHARMA FOR $41 PER SHARE IN AN ALL CASH TRANSACTION EISAI TO ACQUIRE MGI PHARMA FOR $41 PER SHARE IN AN ALL CASH TRANSACTION Tokyo, Japan, and Bloomington, MN, December 10, 2007 - Eisai Co., Ltd. (TSE: 4523.JP) ("Eisai"), a research-based Read more... |
Get more Eisai coverage at:
Paid Research Reports
- Pipeline Insight: Nosocomial Vaccines - Minefield or Goldmine?
- Drug Approval Trends at the FDA and EMEA: Process improvements, heightened scrutiny and industry response
- Biotech 2008 – life sciences industry report (online & print)
- Is there a market for alcoholism pharmacotherapies?
- New report provides Rheumatoid Arthritis market insight